Thiosemicarbazones from the old to new: iron chelators that are more than just ribonucleotide reductase inhibitors Y Yu, DS Kalinowski, Z Kovacevic, AR Siafakas, PJ Jansson, C Stefani, ... Journal of medicinal chemistry 52 (17), 5271-5294, 2009 | 456 | 2009 |
Tuning cell cycle regulation with an iron key Y Yu, Z Kovacevic, DR Richardson Cell cycle 6 (16), 1982-1994, 2007 | 280 | 2007 |
Design, synthesis, and characterization of novel iron chelators: Structure− activity relationships of the 2-benzoylpyridine thiosemicarbazone series and their 3-nitrobenzoyl … DS Kalinowski, Y Yu, PC Sharpe, M Islam, YT Liao, DB Lovejoy, N Kumar, ... Journal of medicinal chemistry 50 (15), 3716-3729, 2007 | 277 | 2007 |
Chelators at the cancer coalface: desferrioxamine to Triapine and beyond Y Yu, J Wong, DB Lovejoy, DS Kalinowski, DR Richardson Clinical Cancer Research 12 (23), 6876-6883, 2006 | 246 | 2006 |
Iron chelators for the treatment of cancer Y Yu, E Gutierrez, Z Kovacevic, F Saletta, P Obeidy, Y Suryo Rahmanto, ... Current medicinal chemistry 19 (17), 2689-2702, 2012 | 196 | 2012 |
Inhibition of spleen tyrosine kinase potentiates paclitaxel-induced cytotoxicity in ovarian cancer cells by stabilizing microtubules Y Yu, S Gaillard, JM Phillip, TC Huang, SM Pinto, NG Tessarollo, Z Zhang, ... Cancer cell 28 (1), 82-96, 2015 | 165 | 2015 |
Bp44mT: an orally active iron chelator of the thiosemicarbazone class with potent anti‐tumour efficacy Y Yu, YS Rahmanto, DR Richardson British journal of pharmacology 165 (1), 148-166, 2012 | 119 | 2012 |
Cellular iron depletion stimulates the JNK and p38 MAPK signaling transduction pathways, dissociation of ASK1-thioredoxin, and activation of ASK1 Y Yu, DR Richardson Journal of Biological Chemistry 286 (17), 15413-15427, 2011 | 111 | 2011 |
Role of glutaredoxin1 and glutathione in regulating the activity of the copper-transporting P-type ATPases, ATP7A and ATP7B WCJ Singleton, KT McInnes, MA Cater, WR Winnall, R McKirdy, Y Yu, ... Journal of biological chemistry 285 (35), 27111-27121, 2010 | 93 | 2010 |
The medicinal chemistry of novel iron chelators for the treatment of cancer Z Kovacevic, D S Kalinowski, D B Lovejoy, Y Yu, Y Suryo Rahmanto, ... Current topics in medicinal chemistry 11 (5), 483-499, 2011 | 85 | 2011 |
Melanotransferrin: search for a function YS Rahmanto, S Bal, KH Loh, Y Yu, DR Richardson Biochimica et Biophysica Acta (BBA)-General Subjects 1820 (3), 237-243, 2012 | 65 | 2012 |
Ovarian cancer stem cells and their role in drug resistance Z Pieterse, MA Amaya-Padilla, T Singomat, M Binju, BD Madjid, Y Yu, ... The International Journal of Biochemistry & Cell Biology 106, 117-126, 2019 | 63 | 2019 |
Therapeutic inducers of apoptosis in ovarian cancer M Binju, MA Amaya-Padilla, G Wan, H Gunosewoyo, Y Suryo Rahmanto, ... Cancers 11 (11), 1786, 2019 | 60 | 2019 |
The potent and novel thiosemicarbazone chelators di-2-pyridylketone-4, 4-dimethyl-3-thiosemicarbazone and 2-benzoylpyridine-4, 4-dimethyl-3-thiosemicarbazone affect crucial … Y Yu, YS Rahmanto, CL Hawkins, DR Richardson Molecular pharmacology 79 (6), 921-931, 2011 | 57 | 2011 |
Inactivation of Arid1a in the endometrium is associated with endometrioid tumorigenesis through transcriptional reprogramming Y Suryo Rahmanto, W Shen, X Shi, X Chen, Y Yu, ZC Yu, T Miyamoto, ... Nature communications 11 (1), 2717, 2020 | 55 | 2020 |
Drug repositioning of mevalonate pathway inhibitors as antitumor agents for ovarian cancer Y Kobayashi, H Kashima, YS Rahmanto, K Banno, Y Yu, Y Matoba, ... Oncotarget 8 (42), 72147, 2017 | 55 | 2017 |
Mechanisms underlying acquired platinum resistance in high grade serous ovarian cancer-a mini review M Binju, MA Padilla, T Singomat, P Kaur, YS Rahmanto, PA Cohen, Y Yu Biochimica et Biophysica Acta (BBA)-General Subjects 1863 (2), 371-378, 2019 | 52 | 2019 |
Mechanism of the induction of endoplasmic reticulum stress by the anti-cancer agent, di-2-pyridylketone 4, 4-dimethyl-3-thiosemicarbazone (Dp44mT): Activation of PERK/eIF2α … AM Merlot, NH Shafie, Y Yu, V Richardson, PJ Jansson, S Sahni, ... Biochemical Pharmacology 109, 27-47, 2016 | 40 | 2016 |
Inhibition of ovarian tumor cell invasiveness by targeting SYK in the tyrosine kinase signaling pathway Y Yu, Y Suryo Rahmanto, MH Lee, PH Wu, JM Phillip, CH Huang, ... Oncogene 37 (28), 3778-3789, 2018 | 27 | 2018 |
Proteome-wide tyrosine phosphorylation analysis reveals dysregulated signaling pathways in ovarian tumors*[S] G Song, L Chen, B Zhang, Q Song, Y Yu, C Moore, TL Wang, IM Shih, ... Molecular & Cellular Proteomics 18 (3), 448-460, 2019 | 23 | 2019 |